P-275First-line pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma: randomized, phase 3 KEYNOTE-177 study

ABSTRACT:

SUBMITTER: Luis D 

PROVIDER: S-EPMC4984061 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature